Theragen Etex Co.Ltd (066700) - Net Assets
Based on the latest financial reports, Theragen Etex Co.Ltd (066700) has net assets worth ₩152.04 Billion KRW (≈ $103.03 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩253.33 Billion ≈ $171.68 Million USD) and total liabilities (₩101.29 Billion ≈ $68.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Theragen Etex Co.Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩152.04 Billion |
| % of Total Assets | 60.02% |
| Annual Growth Rate | 14.83% |
| 5-Year Change | -28.53% |
| 10-Year Change | 120.75% |
| Growth Volatility | 46.04 |
Theragen Etex Co.Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Theragen Etex Co.Ltd's net assets have evolved over time, based on quarterly financial data. See Theragen Etex Co.Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Theragen Etex Co.Ltd (2005–2025)
The table below shows the annual net assets of Theragen Etex Co.Ltd from 2005 to 2025. For live valuation and market cap data, see 066700 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩159.17 Billion ≈ $107.87 Million |
+21.93% |
| 2024-12-31 | ₩130.54 Billion ≈ $88.47 Million |
-14.64% |
| 2023-12-31 | ₩152.93 Billion ≈ $103.64 Million |
+6.50% |
| 2022-12-31 | ₩143.60 Billion ≈ $97.31 Million |
-35.52% |
| 2021-12-31 | ₩222.70 Billion ≈ $150.92 Million |
-40.47% |
| 2020-12-31 | ₩374.12 Billion ≈ $253.54 Million |
+175.37% |
| 2019-12-31 | ₩135.86 Billion ≈ $92.07 Million |
+67.90% |
| 2018-12-31 | ₩80.92 Billion ≈ $54.84 Million |
-6.91% |
| 2017-12-31 | ₩86.93 Billion ≈ $58.91 Million |
+20.55% |
| 2016-12-31 | ₩72.10 Billion ≈ $48.86 Million |
+4.77% |
| 2015-12-31 | ₩68.82 Billion ≈ $46.64 Million |
-16.06% |
| 2014-12-31 | ₩82.00 Billion ≈ $55.57 Million |
+2.93% |
| 2013-12-31 | ₩79.67 Billion ≈ $53.99 Million |
+11.00% |
| 2012-12-31 | ₩71.77 Billion ≈ $48.64 Million |
+27.80% |
| 2011-12-31 | ₩56.16 Billion ≈ $38.06 Million |
+14.16% |
| 2010-12-31 | ₩49.19 Billion ≈ $33.34 Million |
+8.28% |
| 2009-12-31 | ₩45.43 Billion ≈ $30.79 Million |
+73.38% |
| 2008-12-31 | ₩26.20 Billion ≈ $17.76 Million |
+41.17% |
| 2007-12-31 | ₩18.56 Billion ≈ $12.58 Million |
+61.50% |
| 2006-12-31 | ₩11.49 Billion ≈ $7.79 Million |
+14.76% |
| 2005-12-31 | ₩10.01 Billion ≈ $6.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Theragen Etex Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28877374000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩139.28 Billion | 100.21% |
| Total Equity | ₩138.99 Billion | 100.00% |
Theragen Etex Co.Ltd Competitors by Market Cap
The table below lists competitors of Theragen Etex Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Huneed Tech
KO:005870
|
$47.82 Million |
|
Bareket Capital Ltd
TA:BRKT
|
$47.85 Million |
|
Taekyung Chem
KO:006890
|
$47.85 Million |
|
Liberty Shoes Limited
NSE:LIBERTSHOE
|
$47.86 Million |
|
Francotyp-Postalia Holding AG
F:FPH
|
$47.81 Million |
|
Sequana Medical NV
BR:SEQUA
|
$47.76 Million |
|
B&B Triplewall Containers Limited
NSE:BBTCL
|
$47.76 Million |
|
Victory Square Technologies Inc
F:6F6
|
$47.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Theragen Etex Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 112,146,086,090 to 138,994,287,320, a change of 26,848,201,230 (23.9%).
- Net income of 10,600,469,350 contributed positively to equity growth.
- Dividend payments of 99,135,600 reduced retained earnings.
- New share issuances of 12,996,638,030 increased equity.
- Other factors increased equity by 3,350,229,450.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩10.60 Billion | +7.63% |
| Dividends Paid | ₩99.14 Million | -0.07% |
| Share Issuances | ₩13.00 Billion | +9.35% |
| Other Changes | ₩3.35 Billion | +2.41% |
| Total Change | ₩- | 23.94% |
Book Value vs Market Value Analysis
This analysis compares Theragen Etex Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.88x to 0.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2634.83 | ₩2315.00 | x |
| 2017-12-31 | ₩2908.53 | ₩2315.00 | x |
| 2018-12-31 | ₩2657.75 | ₩2315.00 | x |
| 2019-12-31 | ₩4445.60 | ₩2315.00 | x |
| 2020-12-31 | ₩11711.29 | ₩2315.00 | x |
| 2021-12-31 | ₩6958.10 | ₩2315.00 | x |
| 2022-12-31 | ₩4486.69 | ₩2315.00 | x |
| 2023-12-31 | ₩4239.95 | ₩2315.00 | x |
| 2024-12-31 | ₩3503.98 | ₩2315.00 | x |
| 2025-12-31 | ₩3789.03 | ₩2315.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Theragen Etex Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.63%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.90%
- • Asset Turnover: 1.05x
- • Equity Multiplier: 1.85x
- Recent ROE (7.63%) is above the historical average (0.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.86% | 0.46% | 0.69x | 2.69x | ₩-3.00 Billion |
| 2010 | 2.16% | 1.18% | 0.82x | 2.22x | ₩-3.46 Billion |
| 2013 | 1.79% | 1.46% | 0.75x | 1.63x | ₩-6.08 Billion |
| 2014 | 2.10% | 1.50% | 0.85x | 1.65x | ₩-6.02 Billion |
| 2015 | -11.87% | -8.26% | 0.72x | 2.00x | ₩-15.05 Billion |
| 2016 | 3.09% | 2.20% | 0.72x | 1.95x | ₩-4.98 Billion |
| 2017 | 1.47% | 1.18% | 0.74x | 1.67x | ₩-7.42 Billion |
| 2018 | -12.63% | -8.70% | 0.67x | 2.16x | ₩-18.31 Billion |
| 2019 | 32.13% | 31.61% | 0.57x | 1.78x | ₩30.06 Billion |
| 2020 | -2.40% | -6.27% | 0.27x | 1.43x | ₩-46.38 Billion |
| 2021 | -5.32% | -7.12% | 0.48x | 1.57x | ₩-34.12 Billion |
| 2022 | 6.66% | 5.01% | 0.77x | 1.72x | ₩-4.80 Billion |
| 2023 | 19.32% | 12.11% | 0.89x | 1.79x | ₩12.64 Billion |
| 2024 | -36.55% | -16.42% | 1.05x | 2.11x | ₩-52.20 Billion |
| 2025 | 7.63% | 3.90% | 1.05x | 1.85x | ₩-3.30 Billion |
Industry Comparison
This section compares Theragen Etex Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $84,654,166,830
- Average return on equity (ROE) among peers: -2.40%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Theragen Etex Co.Ltd (066700) | ₩152.04 Billion | 0.86% | 0.67x | $47.81 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.82 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $37.74 Billion | 28.99% | 1.00x | $26.85 Million |
| NatureCell Co.Ltd (007390) | $57.16 Billion | -11.92% | 0.64x | $1.10 Billion |
| Sam-A Pharm. Co. Ltd (009300) | $156.10 Billion | 3.72% | 0.08x | $57.12 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $228.48 Billion | -9.06% | 0.28x | $82.40 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $47.60 Million |
| Oscotec Inc (039200) | $46.29 Billion | 7.50% | 0.52x | $755.10 Million |
| EstechPharma Co. Ltd (041910) | $72.13 Billion | -1.21% | 0.27x | $40.76 Million |
| Komipharm International Co. Ltd (041960) | $76.13 Billion | -8.60% | 0.75x | $338.89 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $30.93 Billion | 3.34% | 0.42x | $26.52 Million |
About Theragen Etex Co.Ltd
Theragen Etex Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers drugs in the fields of circulatory, respiratory, digestive, antibiotics, antifungals, analgesic, endocrine and metabolic, hepatoprotective, psychotropic, urinary system, skeletal muscle, PMS, anthelmintic, nutrition, and others. The company wa… Read more